Stevanato Group S.p.A. (NYSE:STVN) Short Interest Update

Stevanato Group S.p.A. (NYSE:STVN) was the target of a large decline in short interest in June. As of June 15th, there was short interest totalling 2,620,000 shares, a decline of 14.9% from the May 31st total of 3,080,000 shares. Currently, 5.3% of the shares of the stock are short sold. Based on an average daily volume of 655,600 shares, the days-to-cover ratio is currently 4.0 days.

Wall Street Analyst Weigh In

STVN has been the topic of a number of research reports. BNP Paribas initiated coverage on shares of Stevanato Group in a report on Monday, April 22nd. They issued an “outperform” rating on the stock. Stephens reiterated an “overweight” rating and issued a $38.00 target price on shares of Stevanato Group in a report on Monday, March 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $30.00 target price on shares of Stevanato Group in a report on Monday, April 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of €34.17 ($36.74).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Natixis Advisors L.P. grew its position in Stevanato Group by 1.9% during the fourth quarter. Natixis Advisors L.P. now owns 23,858 shares of the company’s stock valued at $651,000 after purchasing an additional 449 shares in the last quarter. Personal CFO Solutions LLC grew its position in Stevanato Group by 4.6% during the fourth quarter. Personal CFO Solutions LLC now owns 12,186 shares of the company’s stock valued at $333,000 after purchasing an additional 534 shares in the last quarter. First Horizon Advisors Inc. grew its position in Stevanato Group by 14.1% during the fourth quarter. First Horizon Advisors Inc. now owns 5,311 shares of the company’s stock valued at $145,000 after purchasing an additional 657 shares in the last quarter. Fifth Third Bancorp grew its position in Stevanato Group by 23.6% during the first quarter. Fifth Third Bancorp now owns 4,956 shares of the company’s stock valued at $159,000 after purchasing an additional 947 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Stevanato Group by 54.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock valued at $84,000 after purchasing an additional 1,086 shares in the last quarter.

Stevanato Group Stock Up 2.1 %

Shares of Stevanato Group stock traded up €0.39 ($0.42) during trading on Monday, hitting €18.73 ($20.14). The stock had a trading volume of 498,000 shares, compared to its average volume of 483,109. The stock has a 50 day simple moving average of €21.12 and a 200 day simple moving average of €26.78. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.35 and a current ratio of 1.92. Stevanato Group has a 1 year low of €16.56 ($17.81) and a 1 year high of €36.30 ($39.03).

Stevanato Group (NYSE:STVN) last released its earnings results on Thursday, May 9th. The company reported €0.09 ($0.10) earnings per share for the quarter, missing the consensus estimate of €0.12 ($0.13) by (€0.03) (($0.03)). Stevanato Group had a return on equity of 12.61% and a net margin of 12.57%. The firm had revenue of €256.24 million during the quarter, compared to analysts’ expectations of €261.28 million. On average, analysts predict that Stevanato Group will post 0.54 earnings per share for the current fiscal year.

Stevanato Group Announces Dividend

The business also recently disclosed an annual dividend, which will be paid on Monday, July 15th. Investors of record on Tuesday, June 4th will be given a dividend of $0.053 per share. This represents a yield of 0.29%. The ex-dividend date of this dividend is Tuesday, June 4th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.